Once-weekly taspoglutide was superior to twice-daily ... and hypersensitivity reactions. Clearly, GLP-1 receptor agonists may not be appropriate for all patients with type 2 diabetes, as they ...

Data from the two Phase III trials showed that once-weekly insulin efsitora induced HbA1C reductions similar to daily insulin ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

The results come just a few weeks after a once-weekly injectable GLP-1 drug CT-388 – also sourced from Carmot – achieved an average weight loss of 18.8% at 24 weeks in a phase 1b trial ...

New research published in NEJM and presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid (9-13 Sept) shows that a new class of insulin that is ...

Offering comprehensive, seamless obesity and digestive health support is the best way for employers to address rising costs ...

On the heels of disappointing low-dose data results, Zealand Pharma is back with separate findings for its GLP-1/GLP-2 ...

In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists ... QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa (efsitora ...

Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 ... acting GLP1 to treat those who are unable to tolerate once weekly shots. This program would require no material changes ...

They add, "A once-weekly insulin has the potential to simplify ... basal insulin over current basal insulin preparations." On GLP-1 agonists, they add, "Given treatment guidelines and ...

In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1C ... results from the QWINT-2 phase 3 trial evaluating once-weekly ...